Atai Psychedelics - Search News

Psychedelic drug stocks soar

ATAI stock soars on track for best day on Trump psychedelics push and Wall Street cheers

Canaccord analyst Sumant Kulkarni raised the firm's price target on AtaiBeckley to $15 from $14 and kept a ‘Buy’ rating on the shares. ・Atai is now preparing for its investigational psychedelic drug BPL-003 to enter a late-stage trial this quarter.

· 7h

Psychedelic drug stocks soar as Trump fast‑tracks FDA reviews

· 2h

Trump Just Fast-Tracked Psychedelic Treatments: 3 Under-the-Radar Stocks That Could Be About to Soar

· 8h

Trump Pushes for Speedy Psychedelic Approvals, Sending Stocks Surging

Psychedelic drug stocks surged Monday after President Trump signed an executive order Saturday aimed at speeding up research and patient access to new treatments for mental health conditions.

· 11h

FDA pushes psychedelic therapy research for PTSD

· 1d

Trump Fast-Tracks Psychedelic Medicine After Hearing Antidepressant Effectiveness Data: “That’s Not Great”

· 1d

Trump Loosens Restrictions on Psychedelic Drugs

The drugs include LSD, ecstasy and psilocybin.

· 1d

Trump signs order pushing psychedelics research after Joe Rogan call

· 1d

Trump rolls out Joe Rogan for White House psychedelics announcement and jokes he’d like some meds for anxiety

16hon MSN

Psychedelic stocks rally after Trump orders faster PTSD research; Compass Pathways, Atai lead gains

Psychedelic-related stocks rose in premarket trading after President Donald Trump signed an executive order aimed at accelerating research and expanding access to substances used abroad to treat post-traumatic stress disorder.

14don MSN

Deutsche Bank Confident of AtaiBeckley Inc. (ATAI) Growth Prospects on Psychedelic Medicines

AtaiBeckley Inc. (NASDAQ:ATAI) is one of the best multibagger penny stocks to invest in. On March 27, Deutsche Bank initiated coverage of AtaiBeckley Inc. (NASDAQ:ATAI) with a Buy rating and a $12 price target.

Blockonomi

Enveric Biosciences (ENVB) Stock Explodes 160%+ Following Trump’s Psychedelic Executive Order

Enveric Biosciences (ENVB) stock exploded 160%+ after Trump's executive order to accelerate psychedelic drug reviews and $50M ibogaine research commitment.

AtaiBeckley’s BPL-003 Depression Data Sharpen Clinical Path And Investor Focus

AtaiBeckley (NasdaqGM: ATAI) reported peer reviewed Phase 2a results for its BPL-003 program in treatment resistant depression. The study showed a rapid and sustained antidepressant response from a single intranasal dose,

Insider Monkey

ATAI Life Sciences (ATAI) Rated as ‘Outperform’ at Oppenheimer on Psychedelic Prospects

Atai Life Sciences (NASDAQ:ATAI) is one of the best multibagger penny stocks to buy according to analysts. On July 29, Oppenheimer initiated coverage of the stock with an ‘Outperform’ rating and a $14 price target. The positive stance comes as the ...

KELOLAND News

atai Life Sciences Announces Strategic Investment in Beckley Psytech to Accelerate the Clinical Development of Short-Duration Psychedelics

NEW YORK and BERLIN, Jan. 04, 2024 (GLOBE NEWSWIRE) -- atai Life Sciences (NASDAQ: ATAI) (“atai” or “Company”), a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders, today announced a strategic ...

NBC 7 San Diego

Peter Thiel-Backed Psychedelics Start-Up Plans to Raise $100 Million in IPO

ATAI Life Sciences, a biopharmaceutical company aiming to make psychedelic drugs to treat mental health disorders, announced that it is planning to raise $100 million in an initial public offering. Stream San Diego News for free, 24/7, wherever you are ...

Insider Monkey

H.C. Wainwright Affirms ‘Buy’ Rating on Atai Life Sciences N.V. (ATAI) on Psychedelic Prospects

Atai Life Sciences N.V. (NASDAQ:ATAI) is one of the best healthcare penny stocks to buy now. On September 15, H.C. Wainwright reiterated a ‘Buy’ rating on the stock and a $15 price target. The positive stance follows a meeting between the research firm ...